MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 41.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 319,933 shares of the medical equipment provider's stock after purchasing an additional 94,452 shares during the period. Lantheus comprises 2.0% of MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income's holdings, making the stock its 4th biggest holding. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income owned about 0.47% of Lantheus worth $17,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in LNTH. City State Bank acquired a new stake in shares of Lantheus during the fourth quarter worth approximately $83,000. Fairfield Bush & CO. acquired a new stake in shares of Lantheus during the first quarter worth approximately $177,000. Baker Tilly Wealth Management LLC acquired a new stake in shares of Lantheus during the first quarter worth approximately $220,000. Truist Financial Corp acquired a new stake in shares of Lantheus during the first quarter worth approximately $283,000. Finally, Virginia Retirement Systems ET AL acquired a new stake in shares of Lantheus during the first quarter worth approximately $293,000. 97.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 1,277 shares of Lantheus stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $58.19, for a total transaction of $74,308.63. Following the sale, the director now owns 32,703 shares in the company, valued at $1,902,987.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, CAO Andrea Sabens sold 1,093 shares of the business's stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $71.47, for a total transaction of $78,116.71. Following the completion of the sale, the chief accounting officer now directly owns 63,162 shares of the company's stock, valued at approximately $4,514,188.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gerard Ber sold 1,277 shares of the company's stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $58.19, for a total value of $74,308.63. Following the completion of the sale, the director now directly owns 32,703 shares of the company's stock, valued at $1,902,987.57. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,798 shares of company stock valued at $1,676,307. 1.60% of the stock is owned by company insiders.

Lantheus Stock Performance

Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The medical equipment provider reported $0.89 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.25. Lantheus had a net margin of 4.88% and a return on equity of 28.88%. The company had revenue of $223.80 million for the quarter, compared to analyst estimates of $204.51 million. During the same quarter last year, the firm posted $0.11 earnings per share. The company's quarterly revenue was up 121.4% compared to the same quarter last year. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 2.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LNTH shares. Truist Financial lifted their target price on shares of Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. B. Riley started coverage on shares of Lantheus in a research note on Monday, May 9th. They issued a "buy" rating and a $91.00 target price for the company. Finally, SVB Leerink lifted their target price on shares of Lantheus from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Friday.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories

• Get a free copy of the StockNews.com research report on Lantheus (LNTH)
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
• Beyond Meat Is Not Beyond Hope, And It's Cheap
• Why Apple Could Be At All-Time Highs By Year End

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.